News | Robotic Systems | May 09, 2019

Stereotaxis Announces Next-generation Robotic Magnetic Navigation and Imaging Systems

Robotic surgery system Genesis RMN to be available in combination with Stereotaxis Imaging Model S next-generation X-ray system

Stereotaxis Announces Next-generation Robotic Magnetic Navigation and Imaging Systems

Robotic electrophysiology operating room including Stereotaxis Genesis RMN and Stereotaxis Imaging Model S systems. Image courtesy of Stereotaxis.

May 9, 2019 – Stereotaxis introduced Stereotaxis Genesis RMN, its next-generation robotic platform that it claims is a significant advancement in robotic magnetic navigation technology.

The Stereotaxis Genesis RMN system provides the established benefits and reliability of robotic magnetic navigation in an architecture that is faster, smaller, lighter and more flexible. Since the original launch of the Niobe I system in 2003, improvements in Stereotaxis’ robotic system have remained iterative. Genesis RMN utilizes novel smaller magnets that rotate along their center of mass and are held by flexible robotic arms. This mechanism allows for instantaneous responsiveness to physician control and the flexibility to accommodate an increased range of motion. The Genesis RMN system’s significant reduction in size will improve the patient experience, according to Stereotaxis, and provides physicians and nurses greater access to the patient during the procedure.

Stereotaxis Genesis RMN is being launched concurrently with Stereotaxis Imaging Model S as an integrated complete solution for a robotic interventional operating room. Stereotaxis Imaging Model S is a single-plane, full-power X-ray system designed to be specifically available with the Genesis RMN system. It includes the C-arm, powered table, motorized boom and large high-definition monitors. Developed in collaboration with Omega Medical Imaging, Stereotaxis Imaging incorporates modern fluoroscopy technology designed to support high-quality imaging while minimizing radiation exposure for patients and physicians. The combination of Genesis RMN with Stereotaxis Imaging in a tightly integrated fashion significantly reduces the cost of acquisition, the ongoing cost of ownership and the complexity of installation of a robotic electrophysiology practice.

“We are enthusiastic about the reinvigorated robotic innovation by Stereotaxis and are excited to see how this technology advances the field of electrophysiology,” said Andrea Natale, M.D., cardiac electrophysiologist and executive medical director, Texas Cardiac Arrhythmia Institute at St. David's Medical Center.

“Dr. Natale and I had the opportunity to observe the Genesis and Stereotaxis Imaging systems in person,” said J. David Burkhardt, M.D., cardiac electrophysiologist, Texas Cardiac Arrhythmia Institute at St. David's Medical Center. “I consider this a significant and impressive leap forward, and am excited to see the positive impact of this innovation on patient care, procedure efficiency and the overall experience in the electrophysiology lab.”

Stereotaxis Genesis RMN is CE marked and available for commercialization across various EU geographies. Availability in other global geographies is subject to regulatory approvals, which will be pursued in the coming months. Stereotaxis Imaging Model S has U.S. Food and Drug Administration (FDA) clearance, CE mark, and is commercially available in the U.S., EU and certain other global geographies. Stereotaxis Imaging Model S is compatible with Niobe.

For more information:

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init